ADVERTISEMENT

Dolat Capital: Laurus Labs’ Strong Beat In Q2, Guidance Maintained  

Dolat Capital: Laurus Labs’ Strong Beat In Q2, Guidance Maintained

The antiviral medication being manufactured in Russia. (Photographer Andrey Rudakov/Bloomberg)
The antiviral medication being manufactured in Russia. (Photographer Andrey Rudakov/Bloomberg)
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More